Is MAZE research on Rallies investment advice?

No. Rallies provides research, data, and educational context for MAZE. It does not provide personalized investment advice.

MAZE (Maze Therapeutics, Inc. Common Stock) Stock Analysis - Financials

Maze Therapeutics, Inc. Common Stock (MAZE) is a publicly traded Healthcare sector company. As of July 31, 2026, MAZE trades at $26.92 with a market cap of $1.53B and a P/E ratio of -10.84. MAZE moved -2.57% today. Year to date, MAZE is -32.31%; over the trailing twelve months it is +82.51%. Its 52-week range spans $6.71 to $53.65. Analyst consensus is strong buy with an average price target of $70.00. Rallies surfaces MAZE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are MAZE's key financials?

MAZE financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. MAZE recently traded at $26.92. Market cap is $1.53B. P/E ratio is -10.84. Revenue is $20.00M.

MAZE Key Metrics

Key financial metrics for MAZE
Metric	Value
Price	$26.92
Market Cap	$1.53B
P/E Ratio	-10.84
EPS	$-2.48
Dividend Yield	0.00%
52-Week High	$53.65
52-Week Low	$6.71
Volume	259.20K
Avg Volume	0
Revenue (TTM)	$20.00M
Net Income	$-122.54M
Gross Margin	0.00%

MAZE Analyst Consensus

8 analysts cover MAZE: 0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $70.00.

Common questions about MAZE

What are MAZE's key financials?: MAZE financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. MAZE recently traded at $26.92. Market cap is $1.53B. P/E ratio is -10.84. Revenue is $20.00M.
Is MAZE research on Rallies investment advice?: No. Rallies provides research, data, and educational context for MAZE. It does not provide personalized investment advice.